SUMMARY REPORT
Quality and Safety Committee
ABM University Health Board
Meeting On 23rd February 2017
Agenda Item: 7.3
Subject
Human Tissue Update
Prepared by
Lisa Wakeman (Governance Officer HTA, Research and Development
Department), Sally Buckland-Jones (SGM Clinical support services ,
Singleton Delivery Unit), Clare Baker (Lead Nurse Burns & Plastic
Surgery), Peter Drew (Consultant Surgeon, Burns & Plastics)
Approved by
Amanda Hall (Interim Director of Therapies & Health Sciences)
Presented by
Christine Morrell, (Executive Director of Therapies & Health Sciences)
Purpose
The purpose of this report is to inform the Quality and Safety
Committee of resolution of issues relating to the Human Tissues Act
and to update on Human Tissue Authority (HTA) Governance
Decision
Approval
Information
X
Other
Healthier
Communities
Excellent
Sustainable
Strong
A fully
Patient
&
Partnerships Engaged &
Outcomes & Accessible
Skilled
Experiences
Service
Workforce
Effective
Governance
X
Executive Summary
All aspects of HTA governance are in order and the Post of Research and Development
HTA Governance Officer is now jointly funded between the University and Health Board to
enable oversight of processes in both organisations for joint governance.
Key Recommendations
The Committee is asked to note the arrangements within the Health Board for compliance
with the Human Tissue Act.
Assurance Framework
The committee ensures that no licensable activities are carried out on Health Board
premises without holding a licence from the HTA.
Next Steps
Submit the application for a joint HTA licence with the University as hub, and the Health
Board as satellite(s) - submission is planned for February 2016 subject to funding
agreement by the University.
MAIN REPORT
ABM University Health Board
Quality and Safety Committee
Meeting On 23rd February 2017
Agenda Item: 7.3
Subject
Human Tissue Update
Prepared by
Lisa Wakeman (Governance Officer HTA, Research and Development
Department), Sally Buckland-Jones (SGM Clinical support services,
Singleton Delivery Unit), Clare Baker (Lead Nurse Burns & Plastic
Surgery), Peter Drew (Consultant Surgeon, Burns & Plastics)
Approved by
Amanda Hall (Interim Director of Therapies & Health Sciences)
Presented by Christine Morrell, (Executive Director of Therapies & Health Sciences)
PURPOSE
The purpose of this report is to inform the Quality and Safety Committee of resolution
of issues relating to the Human Tissues Act and to update on Human Tissue
Authority (HTA) Governance.
1.
INTRODUCTION
The HTA Governance Committee deals with all aspects of removal, storage and use
of human tissue. This is defined as material that has come from a human body and
consists of, or includes human cells. The committee ensures that no licensable
activities are carried out on Health Board premises without holding a license from the
HTA. The committee ensures that all Health Board employees assist the work of the
HTA by compiling and producing records and assist the HTA in carrying out its
power or responsibilities.
2.
3.
MAIN BODY OF REPORT/KEY ISSUES
Aims:



Ensure all tissues obtained for research purposes are removed, stored
and used in compliance with the HTA
HTA Research Licence Application Assessment Visit Outcome – Joint
HTA Research Sector Licence 12651 granted July 2016.
Closure of the Skin Bank (Appendix 1)
HTA inspections are up to date for ABMU Mortuaries. At the last inspections there
were no outstanding actions.
The premises at Princess of Wales Hospital (POW) and Morriston Hospitals are
licensed under HTA for the following:
 Making of a post mortem examination
 Removal from the body of a deceased person (otherwise than in the
course of an anatomical examination or post mortem examination) of
relevant material of which the body consists or which it contains, for use
for a scheduled purpose other than transplantation; and storage of the
body of a deceased person or relevant material which has come from a
human body for use for a scheduled purpose.
Any issues of potential interest to the HTA regarding mortuary are reported directly
to HTA for their advice by the Designated Individual for the Mortuary, Dr Brotto.
HTA licensing compliance action plans and any incidents affecting the mortuary are
monitored via the Pathology Clinical Governance & Risk Management Committee
that meets monthly.
The Post of Research and Development HTA Governance Officer is now jointly
funded between the University and Health Board to enable oversight of processes in
both organisations for joint governance.
4.
WAY FORWARD/ FUTURE REPORTING
The HTA Governance Group would like to be advised on the frequency that the
committee would like to receive update reports.
5.
RECOMMENDATIONS
The Committee is asked to note the arrangements within the Health Board for
compliance with the Human Tissue Act.